Lurbinectedin has shown noteworthy clinical activity in metastatic breast cancer with mutations in BRCA 1/2
Lurbinectedin ( Zepsyre ) has shown noteworthy clinical activity in patients with metastatic breast cancer that have mutations in the BRCA 1 and/or BRCA 2 genes.
A phase II trial has assessed the clinical activity of Lurbinectedin in patients affected by metastatic breast cancer in BRCA 1 and/or BRCA 2 gene mutations.
In patients with BRCA2 mutations, the confirmed overall response rate ( ORR ) was observed to be 61%, the median progression-free survival ( PFS ) was observed to be 5.9 months and the median overall survival ( OS ) was observed to be 26.6 months.
In the prior, untreated PARP population, the confirmed ORR was 72%, this being the highest reported figure in this tumor setting so far.
The 54 breast cancer patients with mutations in the BRCA 1 and/or BRCA 2 genes included in the trial were recruited from 11 Centers in the United States and Spain.
Lurbinectedin is a selective inhibitor of active transcription of protein-coding genes. ( Xagena )
Source: PharmaMar, 2018